Lubrizol Life Science Health

Executive Summary

Lubrizol Life Science Health is a business segment of Lubrizol Corporation, a Berkshire Hathaway company, focused on providing high-performance ingredients, excipients, and drug delivery systems for pharmaceutical, medical device, and nutraceutical markets. With a history dating back to 1928, the company leverages deep expertise in polymer science and formulation technologies to enable enhanced bioavailability, targeted delivery, and improved patient compliance. Its product portfolio includes advanced excipients like Carbopol® and Pemulen™ polymers, as well as medical device coatings and nutraceutical solutions. The company serves a diverse global customer base, partnering with innovators to bring treatments to market. As part of a large, financially stable parent, Lubrizol Life Science Health benefits from significant R&D resources and manufacturing scale, positioning it as a reliable partner in the healthcare supply chain. The segment operates within growing end-markets driven by the rise of biologics, specialty generics, and consumer health trends. While the company does not develop its own branded drugs, its technology platforms are integral to many successful products, providing recurring revenue through material sales and licensing. Given its established market presence and backing, the business is well-positioned for steady growth, though specific financials are not publicly disclosed.

Upcoming Catalysts (preview)

• Q4 2026Expansion of nutraceutical product line through new ingredient launches75% success
• Q2 2027Partnership or licensing deal for next-generation drug delivery platform60% success